Zevra Therapeutics Inc ZVRA
News
Zevra Therapeutics to Present at Upcoming Investor Conferences
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

